June 19, 2025
– If approved, Zemcelpro® is expected to: increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromes be the first and only therapy in the European Union with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative […]
Read moreExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand and modify various cell lines for use in innovative single-use curative therapies for patients with hematological malignancies and other diseases.
Learn more
